Roth MKM Reinstates Buy on Bioceres Crop Solutions, Announces $15 Price Target
$BIOX
Agricultural Chemicals
Industrials
Roth MKM analyst Scott Fortune reinstates Bioceres Crop Solutions (NASDAQ:BIOX) with a Buy and announces $15 price target.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $17.00 | Buy | Canaccord Genuity |
| 7/2/2024 | $15.00 | Buy | ROTH MKM |
| 4/6/2023 | $15.00 | Outperform | Oppenheimer |
| 9/30/2022 | $22.50 | Buy | Canaccord Genuity |
| 10/8/2021 | $21.00 | Buy | ROTH Capital |
Total revenues in 1Q25 were $93.3 million 1Q25 net loss1 was $5.3 million and Adjusted EBITDA1 was $8.5 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal first quarter ended September 30, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Tuesday, November 12, 2024 at 8:30 a.m. Eastern Time to discuss its results for the fiscal first quarter ended September 30, 2024. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Paula Savanti will host the conference call, followed by a question-and-an
Revenues up 18% in 4Q24, consolidating annual revenues of $465 million FY24 GAAP net income at $6.2 million and adjusted EBITDA1 at $81.4 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter and fiscal year ended June 30, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financ
Canaccord Genuity analyst Austin Moeller assumes Bioceres Crop Solutions (NASDAQ:BIOX) with a Buy rating and announces Price Target of $17.
Roth MKM analyst Scott Fortune reinstates Bioceres Crop Solutions (NASDAQ:BIOX) with a Buy and announces $15 price target.
Bioceres Crop Solutions (NASDAQ:BIOX) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.16 by 6.25 percent. This is a 65.12 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $84.000 million which missed the analyst consensus estimate of $98.500 million by 14.72 percent. This is a 10.26 percent decrease over sales of $93.605 million the same period last year.
6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)
20-F - Bioceres Crop Solutions Corp. (0001769484) (Filer)
6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)
SC 13G - Bioceres Crop Solutions Corp. (0001769484) (Subject)
SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)
SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)
Canaccord Genuity resumed coverage of Bioceres with a rating of Buy and set a new price target of $17.00
ROTH MKM resumed coverage of Bioceres with a rating of Buy and set a new price target of $15.00
Oppenheimer initiated coverage of Bioceres with a rating of Outperform and set a new price target of $15.00
Total revenues in 1Q25 were $93.3 million 1Q25 net loss1 was $5.3 million and Adjusted EBITDA1 was $8.5 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal first quarter ended September 30, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Tuesday, November 12, 2024 at 8:30 a.m. Eastern Time to discuss its results for the fiscal first quarter ended September 30, 2024. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Paula Savanti will host the conference call, followed by a question-and-an
Revenues up 18% in 4Q24, consolidating annual revenues of $465 million FY24 GAAP net income at $6.2 million and adjusted EBITDA1 at $81.4 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter and fiscal year ended June 30, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financ